Scarica l'app Stockscreener
36.58
0.30%
0.11
Dopo l'orario di chiusura:
36.58
Precedente Chiudi:
$36.47
Aprire:
$36.4
Volume 24 ore:
229.87K
Relative Volume:
0.45
Capitalizzazione di mercato:
$1.02B
Reddito:
$17.16M
Utile/perdita netta:
$-163.62M
Rapporto P/E:
-6.0164
EPS:
-6.08
Flusso di cassa netto:
$-121.61M
1 W Prestazione:
+4.31%
1M Prestazione:
+19.46%
6M Prestazione:
+64.63%
1 anno Prestazione:
+69.12%
Intervallo 1D:
$36.03
$36.96
Intervallo di 1 settimana:
$35.05
$38.38
Portata 52W:
$12.21
$38.38
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Confronta ANAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
36.58 | 1.02B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
How rising interest rates impact AnaptysBio Inc. stockQuarterly Performance Summary & AI Powered Buy and Sell Recommendations - newser.com
Can AnaptysBio Inc. stock weather global recession2025 Volume Leaders & High Conviction Investment Ideas - newser.com
Using fundamentals and technicals on AnaptysBio Inc.Gap Up & Stepwise Trade Execution Plans - newser.com
Real time alert setup for AnaptysBio Inc. performanceVolume Spike & Reliable Entry Point Alerts - newser.com
What drives AnaptysBio Inc AN6 stock pricePrice Support Zones & Free Unlock Stock Analysis - earlytimes.in
Does AnaptysBio Inc. show high probability of reboundJuly 2025 Highlights & Real-Time Volume Analysis - newser.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Can AnaptysBio Inc. stock beat market expectations this quarterQuarterly Portfolio Report & Technical Confirmation Alerts - newser.com
AnaptysBio FY2025 EPS Estimate Boosted by Leerink Partnrs - MarketBeat
A Look at AnaptysBio's (ANAB) Valuation Following Promising Phase 2b Rosnilimab Results and Analyst Upgrades - Yahoo Finance
Moody Aldrich Partners LLC Sells 23,130 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
How currency fluctuations impact AnaptysBio Inc. stockEarnings Recap Summary & Growth-Oriented Investment Plans - newser.com
Is AnaptysBio Inc. (AN6) stock worth holding before Fed meeting2025 Price Momentum & Free Growth Oriented Trading Recommendations - newser.com
Why AnaptysBio Inc. stock is recommended by analystsPortfolio Risk Report & Intraday High Probability Alerts - newser.com
Is AnaptysBio Inc. stock positioned well for digital economyPortfolio Update Report & Stepwise Entry/Exit Trade Alerts - newser.com
Risk adjusted return profile for AnaptysBio Inc. analyzedQuarterly Market Review & Momentum Based Trading Signals - newser.com
Applying big data sentiment scoring on AnaptysBio Inc.Market Activity Recap & Weekly Sector Rotation Insights - newser.com
How AnaptysBio Inc. stock reacts to job market data2025 Short Interest & Daily Technical Stock Forecast Reports - newser.com
Published on: 2025-10-31 05:16:43 - newser.com
Why AnaptysBio Inc. (AN6) stock could be top winnerTrade Performance Summary & Detailed Earnings Play Alerts - newser.com
Will AnaptysBio Inc. (AN6) stock outperform benchmarksNew Guidance & Verified Trade Idea Suggestions - newser.com
Can AnaptysBio Inc. stock sustain revenue growthTrade Volume Summary & Low Volatility Stock Suggestions - newser.com
Identifying reversal signals in AnaptysBio Inc.Swing Trade & Weekly Hot Stock Watchlists - newser.com
How AnaptysBio Inc. stock benefits from tech adoption2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Published on: 2025-10-31 00:12:04 - newser.com
Will AnaptysBio Inc. stock benefit from sector rotation2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
What analysts say about AnaptysBio Inc stockInsider Trading Compliance & Small Budget Trading Portfolio - earlytimes.in
AnaptysBio, Inc. Hits New 52-Week High at $38.38 - Markets Mojo
Published on: 2025-10-30 00:32:17 - newser.com
Stifel Raises Price Target for AnaptysBio (ANAB) to $80 | ANAB S - GuruFocus
AnaptysBio stock rises after positive rheumatoid arthritis trial data By Investing.com - Investing.com Philippines
AnaptysBio stock rises after positive rheumatoid arthritis trial data - Investing.com
Anaptys announces new positive phase 2b trial results for rosnilimab in rheumatoid arthritis - MarketScreener
AnaptysBio (ANAB) Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial - GuruFocus
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):